Investors

Annual report for 2020

Read the report here
Latest news

News
About us

Abliva
Investor relations

General meeting
Development

Primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the ability of cells to convert energy. The disorders can manifest differently depending on the organs affected and have historically been viewed as clinical syndromes,
Investor relations

Investors

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects.
Our team
Events and Presentations
Contact
Our partners and advisers
General meeting
Financial Calendar
Event

European Biotech Investor Days

Abliva participated at the virtual European Biotech Investor Days, Hosted by Solebury Trout, on 7 April 2021. CEO Ellen Donnelly presented the company.

See the presentation here
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all